12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Simeprevir: Phase IIa data

Medivir reported interim data from 80 null responders to peginterferon and ribavirin with HCV genotype 1 infection and mild to moderate liver fibrosis (METAVIR scores of F0-F2) in cohort 1 of the open-label, U.S. Phase IIa COSMOS trial evaluating once-daily 150 mg oral simeprevir plus once-daily 400 mg oral sofosbuvir ( GS-7977) with or without ribavirin for 12 or 24 weeks. Specifically, simeprevir plus sofosbuvir for 12 weeks with ribavirin (n=27) led to an RVR at week 4 in 85.2% of patients, an end of treatment response in 100% of patients, an SVR 4 weeks after end of treatment in 96.3% of patients and an SVR8 in 96.3% of patients. Simeprevir plus sofosbuvir for 12 weeks without ribavirin (n=14) led to an RVR at week 4 in 57.1% of...

Read the full 630 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >